Fondaparinux Use in Pulmonary Embolism

Introduction to Fondaparinux

The European Society of Cardiology recommends fondaparinux as an appropriate choice for patients with pulmonary embolism, particularly when heparin-induced thrombocytopenia (HIT) is suspected or confirmed, as fondaparinux does not cause HIT and requires no platelet monitoring 1

For intermediate- or low-risk pulmonary embolism, fondaparinux is recommended over unfractionated heparin when parenteral anticoagulation is initiated, according to the European Heart Journal 2, 3
The major bleeding rate with fondaparinux in the pivotal pulmonary embolism trial was only 1.3%, comparable to unfractionated heparin at 1.1%, as reported in the European Heart Journal 1

Unfractionated heparin is preferred as the initial anticoagulant in hemodynamically unstable patients with high-risk pulmonary embolism, as fondaparinux has not been tested in this setting, according to the European Heart Journal 1
Fondaparinux is explicitly recommended over unfractionated heparin for most patients with intermediate- or low-risk pulmonary embolism when parenteral anticoagulation is chosen, as stated in the European Heart Journal 2, 3, 4

Severe renal failure with creatinine clearance <20 mL/min is an absolute contraindication to fondaparinux, as reported in the European Heart Journal 1
Severe renal impairment (CrCl <30 mL/min) should prompt consideration of alternative anticoagulation, according to the European Heart Journal, although this specific guideline is from Praxis Medical Insights, an alternative source states the same 5

No routine platelet monitoring is required with fondaparinux, unlike heparins, as stated in the European Heart Journal 1
Renal function should be assessed before initiation of fondaparinux given renal clearance, according to the European Heart Journal 1
Weight-adjusted, fixed-dose fondaparinux (5.0 mg for <50 kg, 7.5 mg for 50-100 kg, 10.0 mg for >100 kg) should be given subcutaneously once daily, as recommended in the European Heart Journal 1